Journal
NATURE REVIEWS CANCER
Volume 8, Issue 10, Pages 782-798Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrc2465
Keywords
-
Categories
Funding
- National Health and Medical Research Council of Australia (NHMRC)
- Pfizer Fellowship
- Leukaemia Foundation of Australia
- Bennelong Foundation
- Cancer Council Victoria
- The Cancer Research Institute Predoctoral Emphasis Pathway in Tumour Immunology
Ask authors/readers for more resources
Triggering of tumour cell apoptosis is the foundation of many cancer therapies. Death receptors of the tumour necrosis factor (TNF) superfamily have been largely characterized, as have the signals that are generated when these receptors are activated. TNF-related apoptosis-inducing ligand (TRAIL) receptors (TRAILR1 and TRAILR2) are promising targets for cancer therapy. Herein we review what is known about the molecular control of TRAIL-mediated apoptosis, the role of TRAIL in carcinogenesis and the potential therapeutic utility of recombinant TRAIL and agonistic antibodies against TRAILR1 and TRAILR2.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
